Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hypertrophic cardiomyopathy News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study explores the intersection of immune checkpoint inhibitor myocarditis and hypertrophic obstructive cardiomyopathy, leading to non-ST elevation myocardial infarction (NSTEMI). This research highlights the complexities of cardiac conditions in patients receiving immunotherapy.

A nationwide study in Denmark reveals significant geographic variation in the diagnosis of hypertrophic and arrhythmogenic right ventricular cardiomyopathy. This research highlights potential disparities in healthcare delivery within a universal healthcare system.

A new study presents a noninvasive method for characterizing myocardial diseases with hypertrophic phenotypes using integrated ECG and echocardiographic indices. This research could enhance diagnostic accuracy and patient management in hypertrophic conditions.

A study identifies natural missplicing events exacerbated by a deep-intronic variant in the MYBPC3 gene as a cause of hypertrophic cardiomyopathy. This discovery enhances understanding of the genetic mechanisms underlying this condition.

A recent study highlights left atrium myocardial remodeling as a prognostic marker in pediatric hypertrophic cardiomyopathy, utilizing CMR feature tracking. This research could enhance monitoring and treatment strategies for affected children.

A new care pathway has been established for diagnosing and managing patients with hypertrophic phenotype in the Marche Region, as reported by the Marche Cardiomyopathies Network. This initiative aims to improve patient outcomes through a structured approach.

A recent study explores the use of implantable cardioverter defibrillators (ICDs) in preventing sudden death among high-risk patients with hypertrophic cardiomyopathy. The findings contribute to understanding the effectiveness of ICDs in this specific patient population.

Research shows that rigosertib effectively reverses hypertrophic cardiomyopathy in patients with Noonan syndrome. This finding could lead to new therapeutic strategies for managing this rare condition.

A recent study evaluates the clinical screening yield in pediatric relatives of hypertrophic cardiomyopathy who have tested negative for genetic mutations. The findings may inform future screening protocols and management strategies for at-risk children.

A recent study published in PubMed examines the use of conventional medical treatments for heart failure with reduced ejection fraction in patients with end-stage hypertrophic cardiomyopathy. The findings provide insights into treatment patterns that could inform future clinical practices.

A recent study highlights midventricular hypertrophic cardiomyopathy with apical aneurysm, which can present as persistent ST-segment elevation, potentially mimicking acute myocardial infarction. This discovery emphasizes the need for accurate diagnosis in similar clinical presentations.

A case report details an instance of asystole recorded by an S-ICD in a patient with non-obstructive hypertrophic cardiomyopathy due to SMART pass deactivation. This highlights potential risks associated with device management in this patient population.

A recent study expands the phenotypic spectrum of GYG1-related disease, highlighting its presentation as hypertrophic cardiomyopathy with Brugada phenocopy. This research may inform future diagnostic and therapeutic strategies for affected patients.

A pilot study utilizing whole-exome sequencing has identified rare genetic variants in Egyptian patients with hypertrophic cardiomyopathy. This research contributes to the understanding of genetic factors associated with the disease.

Braveheart Bio, Attovia Therapeutics, and Vogenx are preparing for IPOs to enter competitive markets in hypertrophic cardiomyopathy and cardiometabolic diseases. Braveheart aims to rival Bristol Myers Squibb, while Attovia targets Sanofi and Regeneron's Dupixent.

A systematic review and meta-analysis on exercise training in hypertrophic cardiomyopathy reveals potential benefits for patient outcomes. The study aggregates data to assess the impact of exercise on this condition, providing insights for future research and clinical practice.

A new study reveals that genotype can predict heart failure in patients with hypertrophic cardiomyopathy, independent of traditional markers like LVEF, peak VO2, and NT-proBNP levels. This finding could enhance risk stratification and management strategies for affected individuals.

A new global model evaluates the cost-effectiveness of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy from a Dutch societal perspective. This research provides insights into the economic implications of treatment for this condition.

Servier has entered a $2.65 billion deal with Edgewise Therapeutics, allowing Edgewise to pivot towards cardiovascular programs, including EDG-7500 for hypertrophic cardiomyopathy. This non-dilutive capital will enable Edgewise to advance its pipeline significantly.

A study validates circulating miR-323a-3p and miR-625-3p as biomarkers for classifying hypertrophic cardiomyopathy in patients with Friedreich's ataxia. This research could enhance diagnostic accuracy and patient management in this rare disease.

Not rare diseases news,news about your rare disease.